Immediate or staged complete revascularisation in patients presenting with acute coronary syndrome by number of diseased vessels: a substudy of the BIOVASC randomised trial
EuroIntervention · 2024
DOI: 10.4244/eij-d-23-00762 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift EuroIntervention, 2024. Verfasst von Hala Kakar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Myocardial Infarction, Percutaneous Coronary Intervention, Coronary Artery Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: In patients presenting with acute coronary syndrome (ACS), the number of diseased vessels may affect the efficacy of a complete revascularisation strategy. AIMS: The authors sought to evaluate the safety and efficacy of immediate complete revascularisation (ICR) and staged complete revascularisation (SCR) in patients presenting with ACS stratified by the number of diseased vessels. METHODS: In this prespecified analysis of the BIOVASC trial, ICR was compared with SCR in patients with two-vessel disease (2VD) or three-vessel disease (3VD). The primary endpoint was a composite of all-cause mortality, myocardial infarction (MI), any unplanned ischaemia-driven revascularisation or cerebrovascular events at 1 year after the index procedure. Comparisons were performed using Cox regression. RESULTS: A total of 1,525 patients were enrolled in the BIOVASC trial, of whom 1,177 presented with 2VD and 265 with 3VD. In the 2VD group, 613 patients were assigned to ICR and 564 to SCR. In the 3VD group, 117 patients were assigned to ICR and 148 to SCR. ICR and SCR led to similar results in both the 2VD (hazard ratio [HR] 0.76, 95% confidence interval [CI]: 0.50-1.13; p=0.18) and 3VD groups (HR 0.79, 95% CI: 0.39-1.59; p=0.51) (pinteraction=0.91) in terms of the primary endpoint. ICR was associated with a lower rate of MI in patients with 3VD (HR 0.21, 95% CI: 0.046-0.93; p=0.04) (pinteraction=0.30). CONCLUSIONS: ICR might be an option in patients presenting with extensive 3VD and might be associated with a lower rate of myocardial infarction compared with SCR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Department of Cardiovascular Medicine, University Hospital Leuven, Leuven, Belgium.
- Interventional Cardiology Department, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
- Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
- Cardiology Department, Hospital Clínico de Valladolid, Valladolid, Spain.
Zitieren
APA
Kakar, H., Elscot, J. J., Scarparo, P., Den Dekker, W. K., Bennett, J., Sabaté, M., Esposito, G., Amat-Santos, I., Boersma, E., Van Mieghem, N. M., & Diletti, R. (2024). Immediate or staged complete revascularisation in patients presenting with acute coronary syndrome by number of diseased vessels: a substudy of the BIOVASC randomised trial. EuroIntervention. https://doi.org/10.4244/eij-d-23-00762
Vancouver
Kakar H, Elscot JJ, Scarparo P, Den Dekker WK, Bennett J, Sabaté M, et al. Immediate or staged complete revascularisation in patients presenting with acute coronary syndrome by number of diseased vessels: a substudy of the BIOVASC randomised trial. EuroIntervention. 2024. doi:10.4244/eij-d-23-00762
BibTeX
@article{Kakar2024,
author = {Kakar, Hala and Elscot, Jacob J and Scarparo, Paola and Den Dekker, Wijnand K and Bennett, Johan and Sabaté, Manel and Esposito, Giovanni and Amat-Santos, Ignacio and Boersma, Eric and Van Mieghem, Nicolas M and Diletti, Roberto},
title = {Immediate or staged complete revascularisation in patients presenting with acute coronary syndrome by number of diseased vessels: a substudy of the BIOVASC randomised trial},
journal = {EuroIntervention},
year = {2024},
doi = {10.4244/eij-d-23-00762}
}
EUVIMED